Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017 · see citing works

Mechanisms of Hepatic Fibrogenesis

Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,640 · see citing works

Therapy for Fibrotic Diseases: Nearing the Starting Line

Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655 · see citing works

Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630 · see citing works

Methods of tissue engineering

Atala, A., & Lanza, R. (2002) · Cited by 526 · see citing works

Corrigendum to ‘EASL recommendations on treatment of hepatitis C: Final update of the series’ [J Hepatol 73 (2020) 1170–1218]

European Association for the Study of the Liver (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.006 · Cited by 463 · see citing works

Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice

Saxena, N. K., Ikeda, K., Rockey, D. C., Friedman, S. L., & Anania, F. A. (2002) · Hepatology · doi:10.1053/jhep.2002.32029 · Cited by 382 · see citing works

STAT3 Contributes to the Mitogenic Response of Hepatocytes during Liver Regeneration

Li, W., Liang, X., Kellendonk, C., Poli, V., & Taub, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202807200 · Cited by 307 · cited 1× · see citing works

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats #

Mejías, M., García‐Pras, E., Tiani, C., Miquel, R., Bosch, J., & Fernández, M. (2008) · Hepatology · doi:10.1002/hep.22758 · Cited by 294 · see citing works

Direct Association with and Dephosphorylation of Jak2 Kinase by the SH2-Domain-Containing Protein Tyrosine Phosphatase SHP-1

Jiao, H., Berrada, K., Yang, W., Tabrizi, M. H., Platanias, L. C., & Yi, T. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6985 · Cited by 290 · see citing works

Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target

Wang, H., Lafdil, F., Kong, X., & Gao, B. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.536 · Cited by 268 · see citing works

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

Shah, R. R., Morganroth, J., & Shah, D. R. (2013) · Drug Safety · doi:10.1007/s40264-013-0048-4 · Cited by 252 · see citing works

New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis

Wang, Y., Gao, J., Zhang, D., Zhang, J., Ma, J., & Jiang, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.027 · Cited by 232 · see citing works

Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells

Nieto, N. (2006) · Hepatology · doi:10.1002/hep.21427 · Cited by 227 · see citing works

Kupffer cells mediate leptin-induced liver fibrosis

Wang, J., Leclercq, I., Brymora, J. M., Xu, N., Ramezani–Moghadam, M., London, R. M., Brigstock, D., & George, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.011 · Cited by 210 · see citing works

Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury.

Horiguchi, N., Wang, L., Mukhopadhyay, P., Park, O., Jeong, W.-I., Lafdil, F., Osei-Hyiaman, D., Moh, A., Fu, X.-Y., Pacher, P., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.016 · Cited by 185 · see citing works

STAT proteins – Key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver

Gao, B., Wang, H., Lafdil, F., & Feng, D. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.029 · Cited by 179 · see citing works

Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3

Chen, K., Tai, W., Liu, T., Huang, H., Lin, Y.-C., Shiau, C., Li, P., Chen, P., & Cheng, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3389 · Cited by 172 · see citing works

Advanced Periductal Fibrosis from Infection with the Carcinogenic Human Liver Fluke Opisthorchis viverrini Correlates with Elevated Levels of Interleukin-6† ‡

Sripa, B., Mairiang, E., Thinkhamrop, B., Laha, T., Kaewkes, S., Sithithaworn, P., Tesana, S., Loukas, A. C., Brindley, P. J., & Bethony, J. M. (2009) · Hepatology · doi:10.1002/hep.23134 · Cited by 165 · see citing works

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

Tai, W., Cheng, A., Shiau, C., Huang, H., Huang, J., Chen, P., & Chen, K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.047 · Cited by 158 · see citing works

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

Wörns, M., Weinmann, A., Pfingst, K., Schulte-Sasse, C., Messow, C., Schulze‐Bergkamen, H., Teufel, A., Schuchmann, M., Kanzler, S., Düber, C., et al. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31818ddfc6 · Cited by 146 · see citing works

Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?

Lee, Y. A., & Friedman, S. L. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.03.012 · Cited by 132 · see citing works

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis

Thabut, D., Routray, C., Lomberk, G. A., Shergill, U., Glaser, K. J., Huebert, R. C., Patel, L. S., Masyuk, T. V., Blechacz, B. R. A., Vercnocke, A. J., et al. (2011) · Hepatology · doi:10.1002/hep.24427 · Cited by 104 · see citing works

Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes

Chen, Y.-L., Lv, J., Ye, X., Sun, M., Xu, Q., Liu, C., Min, L., Li, H., Liu, P., & Ding, X. (2011) · Hepatology · doi:10.1002/hep.24254 · Cited by 99 · see citing works

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib

Deng, Y.-R., Ma, H.-D., Tsuneyama, K., Yang, W., Wang, Y., Lu, F.-T., Liu, P., Liu, P., He, X.-S., Diehl, A. M., et al. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.07.008 · Cited by 95 · see citing works

Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity

Chen, K., Tai, W., Hsu, C.-Y., Huang, J., Liu, C., Chen, P., Kim, I., & Shiau, C. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.023 · Cited by 89 · see citing works

Diagnosis and management of chronic hepatitis C virus infection

Gordon, S. (2004) · CRC Press eBooks · doi:10.1201/b13913-6 · Cited by 86 · see citing works

Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis

Su, T., Kao, J., & Liu, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610578 · Cited by 77 · see citing works

Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma

Tai, W., Shiau, C., Chen, P., Chu, P., Huang, H., Liu, C., Huang, J., & Chen, K. (2013) · Hepatology · doi:10.1002/hep.26640 · Cited by 75 · see citing works

Signal Transducer and Activator of Transcription 3 Protects From Liver Injury and Fibrosis in a Mouse Model of Sclerosing Cholangitis

Mair, M., Zollner, G., Schneller, D., Musteanu, M., Fickert, P., Gumhold, J., Schuster, C., Fuchsbichler, A., Bilban, M., Tauber, S., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.049 · Cited by 74 · see citing works

Dissociation Between Liver Inflammation and Hepatocellular Damage Induced by Carbon Tetrachloride in Myeloid Cell–Specific Signal Transducer and Activator of Transcription 3 Gene Knockout Mice

Horiguchi, N., Lafdil, F., Miller, A. M., Park, O., Wang, H., Rajesh, M., Mukhopadhyay, P., Fu, X. Y., Pacher, P., & Gao, B. (2010) · Hepatology · doi:10.1002/hep.23532 · Cited by 65 · see citing works

Fighting against viral hepatitis: Lessons from Taiwan

Chen, D. (2011) · Hepatology · doi:10.1002/hep.24500 · Cited by 61 · see citing works

Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo

Hong, F., Chou, H.-I., Fiel, M. I., & Friedman, S. L. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2325-y · Cited by 60 · see citing works

Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis

Hennenberg, M., Trebicka, J., Kohistani, Z., Stark, C., Nischalke, H. D., Krämer, B., Körner, C., Klein, S., Granzow, M., Fischer, H., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.148 · Cited by 55 · see citing works

Daily genetic profiling indicates JAK/STAT signaling promotes early hepatic stellate cell transdifferentiation

Lakner, A. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i40.5047 · Cited by 49 · see citing works

Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf

Chen, K., Tai, W., Huang, J., Hsu, C.-Y., Chen, W., Cheng, A., Chen, P., & Shiau, C. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.04.007 · Cited by 34 · see citing works

Corrigendum to: “EASL clinical practice guidelines: Management of chronic hepatitis B virus infection” [J Hepatol 2012;57:167–185]

European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.013 · Cited by 27 · see citing works

Liver Cell Culture and Lineage Biology

Macdonald, J. M., Xu, A. S. L., Kubota, H., Liu, H., Moss, N., Lodestro, C., Luntz, T., LeCluyse, E. L., Hamilton, G. A., Rong, Y., et al. (2002) · Elsevier eBooks · doi:10.1016/b978-012436636-7/50126-9 · Cited by 20 · see citing works

Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF‐1α/SLC7A11 pathway

Yuan, S., Wei, C., Liu, G., Zhang, L., Li, J., Li, L., Cai, S., & Fang, L. (2021) · Cell Proliferation · doi:10.1111/cpr.13158 · Cited by 423 · see citing works

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution

Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314 · see citing works

Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells

Devhare, P. B., Sasaki, R., Shrivastava, S., Bisceglie, A. M. D., Ray, R., & Ray, R. B. (2017) · Journal of Virology · doi:10.1128/jvi.02225-16 · Cited by 183 · see citing works

Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis

Jian, C., Fu, J., Cheng, X., Shen, L., Ji, Y., Wang, X., Pan, S., Tian, H., Tian, S., Liao, R., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.011 · Cited by 172 · see citing works

Repurposing of Kinase Inhibitors for Treatment of COVID-19

Weisberg, E., Parent, A., Yang, P. L., Sattler, M., Liu, Q., Liu, Q., Wang, J., Meng, C., Buhrlage, S. J., Gray, N. S., et al. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02851-7 · Cited by 137 · see citing works

Chronic inflammation‐elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance

Li, X., Chen, C. Y., Xiang, D., Qu, L., Sun, W. C., Lu, X., Zhou, T., Chen, S., Ning, B., Cheng, Z., et al. (2017) · Hepatology · doi:10.1002/hep.29372 · Cited by 125 · see citing works

Multifunctional effects of a small-molecule STAT3 inhibitor on NASH and hepatocellular carcinoma in mice

Jung, K. H., Yoo, W., Stevenson, H. L., Deshpande, D., Shen, H., Gagea, M., Yoo, S.-Y., Wang, J., Eckols, T. K., Bharadwaj, U., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2253 · Cited by 124 · see citing works

Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step

Weiskirchen, R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00303 · Cited by 112 · see citing works

Repurposing of drugs as STAT3 inhibitors for cancer therapy

Thilakasiri, P. S., Dmello, R. S., Nero, T. L., Parker, M. W., Ernst, M., & Chand, A. L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.022 · Cited by 111 · see citing works

Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells

Martí-Rodrigo, A., Alegre, F., Moragrega, Á. B., Garcia‐García, F., Martí‐Rodrigo, P., Fernández‐Iglesias, A., Gracia‐Sancho, J., Apostolova, N., Esplugues, J. V., & Blas‐García, A. (2019) · Gut · doi:10.1136/gutjnl-2019-318372 · Cited by 108 · see citing works

Therapeutic targeting of STAT3 with small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis

Tang, M., Chen, Y., Li, B., Sugimoto, H., Yang, S., Yang, C., LeBleu, V. S., McAndrews, K. M., & Kalluri, R. (2021) · The FASEB Journal · doi:10.1096/fj.202002777rr · Cited by 87 · see citing works

Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies

Yao, C., Dai, S., Wang, C., Fu, K., Wu, R. X., Zhao, X., Yao, Y., & Li, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115464 · Cited by 81 · see citing works

Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes

Ma, R., Chen, J., Liang, Y., Lin, S., Zhu, L., Liang, X., & Cai, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.107 · Cited by 73 · see citing works

The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis

Wang, Z., Li, J., Xiao, W., Long, J., & Zhang, H. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0127-3 · Cited by 71 · see citing works

Asiatic acid ameliorates CC l4-induced liver fibrosis in rats: involvement of Nrf2/ARE, NF-κB/IκBα, and JAK1/STAT3 signaling pathways

Fan, J., Chen, Q., Wei, L., Zhou, X., Wang, R., & Zhang, H. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s179876 · Cited by 60 · see citing works

Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment

Zadorozhna, M., Gioia, S. D., Conese, M., & Mangieri, D. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05290-0 · Cited by 57 · see citing works

RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation

Oh, R. S., Haak, A. J., Smith, K. M. J., Ligresti, G., Choi, K. M., Xie, T., Wang, S., Walters, P., Thompson, M. A., Freeman, M., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.209932 · Cited by 55 · see citing works

SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma

Huang, C., Chen, L., Chen, G. L., Chao, T., & Wang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911092 · Cited by 54 · see citing works

Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFβ signalling

Hung, C., Su, T., Chen, Y.-T., Wu, Y., Chen, Y., Lin, S., Lin, S., & Yang, K. (2021) · Gut · doi:10.1136/gutjnl-2021-325065 · Cited by 49 · see citing works

TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathways

Wang, A., Zhang, F., Xu, H., Xu, M., Cao, Y. W., Wang, C., Xu, Y., Su, M., Zhang, M., & Zhuge, Y. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.003 · Cited by 47 · see citing works

Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses

Lundberg, L., Brahms, A., Hooper, I., Carey, B. D., Lin, S., Dahal, B., Narayanan, A., & Kehn‐Hall, K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.07.005 · Cited by 47 · see citing works

Mesenchymal stem cells derived from normal gingival tissue inhibit the proliferation of oral cancer cells in vitro and in vivo

Ji, X., Zhang, Z., Han, Y., Song, J., Xu, X., Jin, J., Su, S., Mu, D., Liu, X., Xu, S., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3715 · Cited by 45 · see citing works

Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease

Jiao, J., Sanchez, J. I., Saldarriaga, Ó. A., Solis, L. M., Tweardy, D. J., Maru, D. M., Stevenson, H. L., & Beretta, L. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100628 · Cited by 45 · see citing works

Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis

Hong, S., Lu, Y., Chen, S.-Y., Hsu, C.-F., Lu, Y.-C., Wang, C., & Huang, K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05876-z · Cited by 41 · see citing works

Luteolin-Mediated Inhibition of Hepatic Stellate Cell Activation via Suppression of the STAT3 Pathway

Cummins, C. B., Wang, X., Lopez, O. N., Graham, G., Tie, H.-Y., Zhou, J., & Radhakrishnan, R. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061567 · Cited by 40 · see citing works

Natural STAT3 inhibitors: A mini perspective

Wang, Z., Hui, C., & Xie, Y. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105169 · Cited by 38 · see citing works

STAT3 inhibition suppresses hepatic stellate cell fibrogenesis: HJC0123, a potential therapeutic agent for liver fibrosis

Lopez, O. N., Bohanon, F. J., Wang, X., Ye, N., Corsello, T., Rojas-Khalil, Y., Chen, H., Chen, H., Zhou, J., & Radhakrishnan, R. S. (2016) · RSC Advances · doi:10.1039/c6ra17459k · Cited by 36 · see citing works

Biomimetic nanoparticles drive the mechanism understanding of shear-wave elasticity stiffness in triple negative breast cancers to predict clinical treatment

Zheng, D., Zhou, J., Qian, L., Liu, X., Chang, C., Tang, S., Zhang, H., & Zhou, S. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.10.025 · Cited by 35 · see citing works

Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration

Ma, W., Tao, L., Wang, X., Liu, Q., Zhang, W., Li, Q., He, C., Xue, D., Zhang, J., & Liu, C. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447883 · Cited by 32 · see citing works

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension

Uschner, F. E., Schueller, F., Nikolova, I., Klein, S., Schierwagen, R., Magdaleno, F., Gröschl, S., Loosen, S. H., Ritz, T., Roderburg, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26333 · Cited by 32 · see citing works

Sorafenib reduces steatosis‐induced fibrogenesis in a human 3D co‐culture model of non‐alcoholic fatty liver disease

Romualdo, G. R., da Silva, T. C., Landi, M. F. D. A., Morais, J. Á., Barbisan, L. F., Vinken, M., de Oliveira, C. P. M. S., & Cogliati, B. (2020) · Environmental Toxicology · doi:10.1002/tox.23021 · Cited by 31 · see citing works

Dual TBK1/IKKɛ inhibitor amlexanox attenuates the severity of hepatotoxin‐induced liver fibrosis and biliary fibrosis in mice

Zhou, Z., Qi, J., Zhao, J., Lim, C. W., Kim, J., & Kim, B. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14817 · Cited by 29 · see citing works

(–)-Catechin-7-O-β-d-Apiofuranoside Inhibits Hepatic Stellate Cell Activation by Suppressing the STAT3 Signaling Pathway

Park, Y. J., Kim, D., Jeong, M. H., Yu, J. S., So, H. M., Bang, I. J., Kim, H. R., Kwon, S., Kim, K. H., & Chung, K. H. (2019) · Cells · doi:10.3390/cells9010030 · Cited by 29 · see citing works

Optimization and Validation of a Novel Three-Dimensional Co-Culture System in Decellularized Human Liver Scaffold for the Study of Liver Fibrosis and Cancer

Thanapirom, K., Caon, E., Papatheodoridi, Μ., Frenguelli, L., Al‐Akkad, W., Zhenzhen, Z., Vilia, M. G., Pinzani, M., Mazza, G., & Rombouts, K. (2021) · Cancers · doi:10.3390/cancers13194936 · Cited by 28 · see citing works

Hepatoprotective Potency of Chrysophanol 8-O-Glucoside from Rheum palmatum L. against Hepatic Fibrosis via Regulation of the STAT3 Signaling Pathway

Park, Y. J., Lee, K. H., Jeon, M. S., Lee, Y. H., Ko, Y., Pang, C., Kim, B., Chung, K. H., & Kim, K. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239044 · Cited by 26 · see citing works

Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation

Shao, M., Zhang, X., Sun, J., Dong, H., Han, X., Yang, Q., Chen, R., Shen, L., Xu, L., Wang, L., et al. (2025) · Exploration · doi:10.1002/exp.70000 · Cited by 26 · see citing works

An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma

Raoul, J., Gilabert, M., Adhoute, X., & Edeline, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1378346 · Cited by 25 · see citing works

EGF receptor–mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signaling

Chiusa, M., Hu, W., Zienkiewicz, J., Chen, X., Zhang, M., Harris, R. C., Vanacore, R., Bentz, J. A., Remuzzi, G., Benigni, A., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.202001120 · Cited by 25 · see citing works

Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells

Saidak, Z., Giacobbi, A., Louandre, C., Sauzay, C., Mammeri, Y., & Galmiche, A. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.038 · Cited by 25 · see citing works

Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds

Huang, X., Cai, H., Ammar, R., Zhang, Y., Wang, Y., Ravi, K., Thompson, J. R., & Járai, G. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00281.2018 · Cited by 24 · see citing works

Human Wharton’s jelly mesenchymal stem cells derived-exosomes enriched by miR-124 promote an anti-fibrotic response in an experimental model of liver fibrosis

Niknam, B., Baghaei, K., Hashemi, S. M., Hatami, B., Zali, M. R., & Amani, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110294 · Cited by 24 · see citing works

Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma

Chung, C., Shih-Wei, W., Sun, W., Shu, C., Kao, Y.-C., Shiao, M., & Chen, C. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.04.014 · Cited by 24 · see citing works

STAT3 Inhibitors in Cancer: A Comprehensive Update

Bharadwaj, U., Kasembeli, M. M., & Tweardy, D. J. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-42949-6_5 · Cited by 23 · see citing works

Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis

Su, T., Shiau, C., Jao, P., Yang, N.-J., Tai, W., Liu, C., Tseng, T., Yang, H., Liu, C., Huang, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01572-z · Cited by 22 · see citing works

Photodynamic therapy activated STAT3 associated pathways: Targeting intrinsic apoptotic pathways to increase PDT efficacy in human squamous carcinoma cells

Qiao, L., Xu, C., Li, Q., Mei, Z., Li, X., Cai, H., & Liu, W. (2015) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2015.11.003 · Cited by 20 · see citing works

Ginkgetin exhibits antifibrotic effects by inducing hepatic stellate cell apoptosis via STAT1 activation

Wang, C., Bai, Y., Li, T., Liu, J., Wang, Y., Ju, S., Yao, W. Q., & Xiong, B. (2024) · Phytotherapy Research · doi:10.1002/ptr.8106 · Cited by 20 · see citing works

Molecular characterization of a precision-cut rat lung slice model for the evaluation of antifibrotic drugs

Huang, X., Li, L., Ammar, R., Zhang, Y., Wang, Y., Ravi, K., Thompson, J. R., & Járai, G. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00339.2018 · Cited by 19 · see citing works

Saikosaponin D alleviates cancer cachexia by directly inhibiting STAT3

Chen, L.-L., Xia, L., Zhang, J., Wang, Y., Chen, J., Guo, C., & Xu, W. (2022) · Phytotherapy Research · doi:10.1002/ptr.7676 · Cited by 18 · see citing works

Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model

Zahavi, T., Lanton, T., Salmon‐Divon, M., Salmon, A. Y., Peretz, T., Galun, E., Axelrod, J. H., & Sonnenblick, A. (2015) · Oncotarget · doi:10.18632/oncotarget.6638 · Cited by 18 · see citing works

Andrographolide derivative as STAT3 inhibitor that protects acute liver damage in mice

Chen, S., Feng, L., Ding, M., Wang, D., Zhao, Q., Wang, Y., Zhou, G., & Wang, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.09.002 · Cited by 18 · see citing works

Recent updates of precision therapy for gastric cancer: Towards optimal tailored management

Joo, M. K., Park, J., & Chun, H. J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4638 · Cited by 17 · see citing works

Advances in the Development of Small Molecule Antivirals against Equine Encephalitic Viruses

Ogorek, T. J., & Golden, J. E. (2023) · Viruses · doi:10.3390/v15020413 · Cited by 13 · see citing works

Recent Advances in Research on Active Compounds Against Hepatic Fibrosis

Liu, C., Li, S., Zhang, C., & Jin, C. H. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230727102016 · Cited by 15 · see citing works

Control of adipogenic commitment by a STAT3-VSTM2A axis

Dow, M. A., Silveira, M. A. D., Poliquin, A., Tribouillard, L., Fournier, É., Trébaol, E., Secco, B., Villot, R., Tremblay, F., Bilodeau, S., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00314.2020 · Cited by 15 · see citing works

Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice

Ma, Z., Liu, X., Dong, H., Xia, D., Wang, L., Chen, Y. Z., & Xiong, Y. (2018) · Parasitology Research · doi:10.1007/s00436-018-5972-x · Cited by 14 · see citing works

STAT3 Inhibition Partly Abolishes IL-33–Induced Bone Marrow–Derived Monocyte Phenotypic Transition into Fibroblast Precursor and Alleviates Experimental Renal Interstitial Fibrosis

Zhu, F., Bai, X., Hong, Q., Cui, S., Wang, X., Xiao, F., Li, J., Zhang, L., Dong, Z., Wang, Y., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801273 · Cited by 13 · see citing works

Lactucin reverses liver fibrosis by inhibiting TGF-β1/STAT3 signaling pathway and regulating short-chain fatty acids metabolism

Qin, D., Han, C. L., Gao, Y., Li, H., & Zhu, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-70253-5 · Cited by 12 · see citing works

Lipophilic Constituents in Salvia miltiorrhiza Inhibit Activation of the Hepatic Stellate Cells by Suppressing the JAK1/STAT3 Signaling Pathway: A Network Pharmacology Study and Experimental Validation

Tang, Y.-X., Liu, M., Liu, L., Zhen, B.-R., Wang, T.-T., Li, N., Lv, N., Zhu, Z., Sun, G., Wang, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.770344 · Cited by 10 · see citing works

Gout drives metabolic dysfunction-associated steatotic liver disease through gut microbiota and inflammatory mediators

Liu, S., Li, F., Cai, Y., Sun, L., Ren, L., Yin, M., Cui, H., Pan, Y., Gang, X., & Wang, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-94118-7 · Cited by 9 · see citing works

Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis

Yang, S., Zhang, R., Deng, W., Chang, S.-C., Li, Y., & Li, S. (2023) · Inflammation Research · doi:10.1007/s00011-023-01776-2 · Cited by 7 · see citing works

Suppression of Liver Fibrogenesis with Photothermal Sorafenib Nanovesicles via Selectively Inhibiting Glycolysis and Amplification of Active HSCs.

Xiang, X., Shao, Y., Xiang, L., Jiao, Q., Zhang, W., Qin, Y., & Chen, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01135 · Cited by 6 · see citing works

The underlying hepatoprotective mechanism of PKC #963 in alcohol or carbon tetrachloride induced liver injury via inhibition of iNOS , COX ‐2, and p‐STAT3 and enhancement of SOD and catalase

Kim, D. S., Lee, H., Sim, D. Y., Park, J. E., Park, Y., Kim, B., Shim, B., & Kim, S. (2022) · Phytotherapy Research · doi:10.1002/ptr.7630 · Cited by 6 · see citing works

Kinase Inhibitor Library Screening Identifies the Cancer Therapeutic Sorafenib and Structurally Similar Compounds as Strong Inhibitors of the Fungal Pathogen Histoplasma capsulatum

Berkes, C. A., Franco, J., Lawson, M., Brann, K., Mermelstein, J., Laverty, D. J., & Connors, A. (2021) · Antibiotics · doi:10.3390/antibiotics10101223 · Cited by 6 · see citing works

Proteomics and Phosphoproteomics Revealed Dysregulated Kinases and Potential Therapy for Liver Fibrosis

Cheng, X., Li, K., Liu, J., Wang, Q., Zhang, Z., Zhang, L., Xie, Y., Chang, L., Zeng, D., Tian, L., et al. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100991 · Cited by 5 · see citing works

HJC0416 Attenuates Fibrogenesis in Activated Hepatic Stellate Cells via STAT3 and NF-κB Pathways

Sommerhalder, C., Cummins, C. B., Wang, X., Ramdas, D., Lopez, O. N., Gu, Y., Zhou, J., & Radhakrishnan, R. S. (2021) · Journal of Surgical Research · doi:10.1016/j.jss.2020.12.045 · Cited by 5 · see citing works

Differential association of STAT3 and HK‐II expression in hepatitis B virus‐ and hepatitis C virus‐related hepatocellular carcinoma

Li, M., Wang, W.-H., Jin, R., Zhang, T., Li, N., Han, Q., Wei, P., & Liu, Z.-W. (2016) · Journal of Medical Virology · doi:10.1002/jmv.24498 · Cited by 6 · see citing works

Connective tissue growth factor in hepatocytes is elevated by carbon tetrachloride via STAT3 activation

Chen, W., Li, Y., Hsu, C., Niu, C., Pen, W., Cheng, K., & Niu, H. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10916 · Cited by 5 · see citing works

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis

Gao, S., Fan, L., Wang, H., Wang, A., Hu, M., Zhang, L., & Sun, G. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02473-1 · Cited by 4 · see citing works

Beneficial effects of ginkgetin on improving nonalcoholic steatohepatitis characterized by bulk and single-cell RNA sequencing analysis

Wang, C., Bai, Y., Li, T., Liu, J., Wang, Y., Ju, S., Yao, W., Xiong, B., & Zhou, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1267445 · Cited by 3 · see citing works

JAK2V617F ‐dependent down regulation of SHP ‐1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF ‐β

Aoun, C., Maslah, N., Ganesan, S., Salomao, N., Gendron, R., Awan-Toor, S., Letort, G., Gou, P., Bonnamy, M., Parietti, V., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70138 · Cited by 3 · see citing works

Targeting hyperactive mitochondria in activated HSCs and inhibition of liver fibrogenesis in mice using sorafenib complex micelles

Li, X., Qin, Y., Li, L., Xiang, X., Zhang, W., Jiao, Q., Shao, Y., Huang, X., Wu, M., Zhou, T., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125058 · Cited by 2 · see citing works

Attenuation of liver stiffness in sorafenib-treated patients with advanced hepatocellular carcinoma

Hung, C., Liu, D., Wu, T., Lee, C., Pan, K., Wang, C., Chai, H.-Y., Yu, M., & Chen, Y. (2017) · Hepatoma Research · doi:10.20517/2394-5079.2016.43 · Cited by 1 · see citing works

Independent regulation of tumorigenesis and fibrosis in non-alcoholic fatty liver disease

Gillman, R., & Hebbard, L. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.08.11 · Cited by 1 · see citing works

Data from Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice

Jung, K. H., Yoo, W., Stevenson, H. L., Deshpande, D., Shen, H., Gagea, M., Yoo, S., Wang, J., Eckols, T. K., Bharadwaj, U., et al. (2023) · doi:10.1158/1078-0432.c.6527099

Dynamical modelling of the RAS-RAF-MEK-ERK pathway in the hepatocellular cells exposed to sorafenib

Giacobbi, A. (2019) · doi:10.70675/132cc3f3z6a08z4c5ezb01azedd647e6676b

Elucidating the role of SHP-1 in TGF-ß resistance in myeloproliferative neoplasms

Aoun, C. (2024) · theses.fr (ABES) · doi:10.70675/3146017czdefbz4c4az96f3z2d837d53ea19

Research progress and future trends in advanced biomaterials for the treatment of liver fibrosis

Li, B., Zhu, R., Lv, Y., & Chen, G. (2026) · Biomedical Materials · doi:10.1088/1748-605x/aea1cd

BindingDB Entry 50001913: Andrographolide derivative as STAT3 inhibitor that protects acute liver damage in mice.

BindingDB (2020) · UC San Diego · doi:10.7270/q2st7sdk

Isoimperatorin regulates hepatic fibrosis through LXRα/β-HMGB1/NLRP3 axis: insights into the apoptosis of activated hepatic stellate cells in hepatic microenvironment

Liu, S., Xuan, M., Gao, C., Wang, C., 廉丽花, Nan, J., Cui, Z., & Wu, Y. (2026) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(26)61226-5

Sorafenib and SC-1 Exhibit Anti-fibrotic Effects Through Signal Transducer and Activator of Transcription 3 Inhibition

Su, T., Shiau, C., Jao, P., Liu, C., Liu, C., Tai, W., Jeng, Y., Yang, H., Tseng, T., Huang, H., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.04.043

Combination of Antioxidant Cocktail and Pregabalin in the Management of Pain in Chronic Pancreatitis After Ductal Clearance: A Randomized, Double-Blinded, Placebo-Controlled Trial

Su, T., Shiau, C., Jao, P., Liu, C., Liu, C., Tai, W., Jeng, Y., Yang, C., Tseng, T., Huang, H., et al. (2015)

The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis

Wang, Z., Li, J., Xiao, W., Long, J., & Zhang, H. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0127-3 · Cited by 71 · see citing works

Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis

Su, T., Shiau, C., Jao, P., Yang, N.-J., Tai, W., Liu, C., Tseng, T., Yang, H., Liu, C., Huang, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01572-z · Cited by 22 · see citing works

STAT3 inhibition suppresses hepatic stellate cell fibrogenesis: HJC0123, a potential therapeutic agent for liver fibrosis

Lopez, O. N., Bohanon, F. J., Wang, X., Ye, N., Corsello, T., Rojas-Khalil, Y., Chen, H., Chen, H., Zhou, J., & Radhakrishnan, R. S. (2016) · RSC Advances · doi:10.1039/c6ra17459k · Cited by 36 · see citing works